Table 1.
Clinical and developmental status of anthrax antibodies targeting biodefense agents
| International non-proprietary name, product name or code | Targeted antigen | Antibody type (Isolation) | Clinical phase or approval year | US Patent reference number |
| Raxibacumab/ABthrax™,a | anti-PA | Recombinant IgG1 mAb (naïve library) | FDA review | 601351 |
| Valortim®/MAb-1303b | anti-PA | Human mAb (transgenic mice) | Phase 1 | 7456264 |
| Anthim®/ETI-204c | anti-PA | Chimeric deimmunized mAb (murine origin) | Phase 1 | 7446182 |
| Thravixa™/AVP-21D9d | anti-PA | Human mAb (hybridoma) | Phase 1 | 7438909, 7442373 |
| Anthrivig™/Anthrax Immune Globulin (AIG) | anti-PA | Polyclonal antibody from AVA human plasma | Phase 1/2 | N/A |
a
Subramanian et al. 2005 and US Patent 7601351.
b
Vitale et al. 2006 and US Patent Number 7456264.
c
Mohamed et al. 2005 and US Patent Number 7446182.
d
Peterson et al. 2007 and US Patents 7438909 and 7442373.